AUMED, a.s. received a grant in the Operational Program Enterprise and Innovation for Competitiveness under the Innovation Call – Innovation Project – Call VIII for a project entitled “TFI Transfer Factor – Medicine”, registration number CZ.01.1.02 / 0.0 / 0.0 / 20_318 / 0026008. The main purpose of this grant is to strengthen the company’s innovative performance and increase market competitiveness.
The aim and intention of the project is to create a new production and control center of AUMED, a.s., which will use the results of its own R&D for the production of an innovated preparation based on the transfer factor (TFI). The innovative immunomodulator will be fully competitive on the world markets.
The project is part of the long-term business concept and strategy of AUMED, a.s.. The project is focused on the production application of development results; specifically for the introduction of a new product (TFI) into standard production.
AUMED has received support for the project titled “Development of an Immunization Product for Protection Against the Causative Agent of…
AUMED has received support for the project “Innovation in the Production of Immunological Preparations,” registration number CZ.01.01.01/02/24_051/0004982. The essence of…
Our subsidiary, AUMED Pharma a.s., is expanding the Phage Glow range with two new product lines: ATOPCARE Atopcare is here…
Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
